Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Methods in Molecular Biology (Clifton, N.J.)|April 3, 2013
AntithrombinMirta Hepner, Vasiliki Karlaftis
Methods in Molecular Biology (Clifton, N.J.)|April 3, 2013
Protein CMirta Hepner, Vasiliki Karlaftis
Methods in Molecular Biology (Clifton, N.J.)|April 3, 2013
Protein SMirta Hepner, Vasiliki Karlaftis
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|October 21, 2015
Importance of post-translational modifications on the function of key haemostatic proteinsVasiliki Karlaftis, Sachin Perera, Paul Monagle, et al.
Clinical Chemistry and Laboratory Medicine|July 5, 2022
Age partitioned and continuous upper reference limits for Ortho VITROS High Sensitivity Troponin I in a healthy paediatric cohortJoel Smith, Vasiliki Karlaftis, Stephen Hearps, et al.
Thrombosis Research|December 17, 2025
The in vitro anticoagulant effect of milvexian in healthy neonates and childrenNatasha Letunica, Vasiliki Karlaftis, Paul Monagle, et al.
Clinical Chemistry and Laboratory Medicine|March 12, 2021
Continuous reference intervals for leukocyte telomere length in children: the method mattersAnalia Lesmana, Pei Tian, Vasiliki Karlaftis, et al.
Pediatric Nephrology (Berlin, Germany)|May 25, 2020
Reference intervals for serum cystatin C in neonates and children 30 days to 18 years oldTengyi Cai, Vasiliki Karlaftis, Stephen Hearps, et al.
Journal of Proteomics|April 15, 2015
Differences in the resting platelet proteome and platelet releasate between healthy children and adultsCharmaine Cini, Christina Yip, Chantal Attard, et al.
Research and Practice in Thrombosis and Haemostasis|April 23, 2026
The <i>in vitro</i> anticoagulant effect of abelacimab in healthy childrenNatasha Letunica, Simon Collett, Vasiliki Karlaftis, et al.
Pageof 3